doxepin has been researched along with Facial Pain in 2 studies
Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.
doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.
Facial Pain: Pain in the facial region including orofacial pain and craniofacial pain. Associated conditions include local inflammatory and neoplastic disorders and neuralgic syndromes involving the trigeminal, facial, and glossopharyngeal nerves. Conditions which feature recurrent or persistent facial pain as the primary manifestation of disease are referred to as FACIAL PAIN SYNDROMES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Doxepin was associated with more stinging or burning, unpleasant taste, and greater drowsiness than the placebo rinse." | 2.79 | Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]). ( Bearden, JD; Dornfeld, KJ; Foote, RL; Klish, MD; Leenstra, JL; Loprinzi, CL; Martenson, JA; Mazurczak, MA; Miller, RC; Novotny, PJ; Puri, DR; Qin, R; Stella, PJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leenstra, JL | 1 |
| Miller, RC | 1 |
| Qin, R | 1 |
| Martenson, JA | 1 |
| Dornfeld, KJ | 1 |
| Bearden, JD | 1 |
| Puri, DR | 1 |
| Stella, PJ | 1 |
| Mazurczak, MA | 1 |
| Klish, MD | 1 |
| Novotny, PJ | 1 |
| Foote, RL | 1 |
| Loprinzi, CL | 1 |
| Tversky, J | 1 |
| Reade, PC | 1 |
| Gerschman, JA | 1 |
| Holwill, BJ | 1 |
| Wright, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy[NCT01156142] | Phase 3 | 155 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
After each dose was administered, patients were asked if they would like to continue rinses with that particular agent. The percentage of patients who expressed an interest in continuing therapy are reported below. (NCT01156142)
Timeframe: Up to 9 days
| Intervention | percentage of patients (Number) |
|---|---|
| Arm I (Doxepin-Placebo) | 77.3 |
| Arm II (Placebo-Doxepin) | 51.5 |
The total drowsiness increase will be calculated by the area under the curve (AUC) adjusting for baseline, with time scale replaced by a numerical scale of 1,2,3,4,5,6. The numerical scale will be used rather than the raw time scale in order to give proper weights to more immediate patient-reported mouth pain outcomes after treatment. The AUC will be calculated by proration when there are terminal missing data. If the missing data are intermittent, simple imputation will be applied to calculate the AUC. The question ('On a scale from 0 to 10, what number best describes your DROWSINESS now?') used 11-point numerical analog scales (0 (no drowsiness) to 10 (extreme drowsiness, leading to sleep) scores) to measure total drowsiness increase. The AUCs for the two treatment arms were compared by using the Wilcoxon rank sum test with 95% CIs. The statistical analysis will be the same as the primary analysis. (NCT01156142)
Timeframe: Up to 9 days
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I (Doxepin-Placebo) | -0.7 |
| Arm II (Placebo-Doxepin) | -2.4 |
The total pain reduction will be calculated by the (average of mouth and throat) area under the curve (AUC) adjusting for baseline, with time scale replaced by a numerical scale of 1,2,3,4,5,6. The numerical scale will be used rather than the raw time scale in order to give proper weights to more immediate patient-reported mouth pain outcomes after treatment. The AUC will be calculated by proration when there are terminal missing data. If the missing data are intermittent, simple imputation will be applied to calculate the AUC. The question ('On a scale from 0 to 10, what number best describes your MOUTH PAIN due to your radiation treatment now?') used 11-point numerical analog scales (0 (no pain) to 10 (worst pain imaginable or possible) scores) to measure pain. The AUCs for the two treatment arms were compared by using the Wilcoxon rank sum test with 95% CIs. (NCT01156142)
Timeframe: Baseline and Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I (Doxepin-Placebo) | -9.1 |
| Arm II (Placebo-Doxepin) | -4.7 |
The total stinging or burning from the oral rinse will be calculated by the area under the curve (AUC) adjusting for baseline, with time scale replaced by a numerical scale of 1,2,3,4,5,6. The numerical scale will be used rather than the raw time scale in order to give proper weights to more immediate patient-reported mouth pain outcomes after treatment. The AUC will be calculated by proration when there are terminal missing data. If the missing data are intermittent, simple imputation will be applied to calculate the AUC. The question ('On a scale from 0 to 10, what number best describes any STINGING OR BURNING FROM THE ORAL RINSE now?') used 11-point numerical analog scales (0 (no stinging or burning) to 10 (worst stinging or burning possible) scores) to total stinging or burning from the oral rinse. The AUCs for the two treatment arms were compared by using the Wilcoxon rank sum test with 95% CIs.The statistical analysis will be the same as the primary analysis. (NCT01156142)
Timeframe: Up to 9 days
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I (Doxepin-Placebo) | 9.6 |
| Arm II (Placebo-Doxepin) | 4.0 |
The total taste of the oral rinse will be calculated by the area under the curve (AUC) adjusting for baseline, with time scale replaced by a numerical scale of 1,2,3,4,5,6 , and analyzed in the same way as the primary endpoint. The numerical scale will be used rather than the raw time scale in order to give proper weights to more immediate patient-reported mouth pain outcomes after treatment. The AUC will be calculated by proration when there are terminal missing data. If the missing data are intermittent, simple imputation will be applied to calculate the AUC. The question ('On a scale from 0 to 10, what number best describes the TASTE OF THE ORAL RINSE now?') used 11-point numerical analog scales (0 (acceptable taste) to 10(terrible taste), with higher values representing worse outcome) to evaluate the total taste of the oral rinse. The AUCs for the two treatment arms were compared by using the Wilcoxon rank sum test with 95% CIs. (NCT01156142)
Timeframe: Up to 9 days
| Intervention | units on a scale (Mean) |
|---|---|
| Arm I (Doxepin-Placebo) | 7.7 |
| Arm II (Placebo-Doxepin) | 5.1 |
The incidence of utilizing additional analgesics between 2 and 4 hours after the initial mouthwash will be compared between the arms by the Chi-square test . (NCT01156142)
Timeframe: Up to 9 days
| Intervention | percentage of patients (Number) | |
|---|---|---|
| At 2 hours after the initial mouthwash | At 4 hours after the initial mouthwash | |
| Arm I (Doxepin-Placebo) | 8.8 | 16.9 |
| Arm II (Placebo-Doxepin) | 2.9 | 14.5 |
1 trial available for doxepin and Facial Pain
| Article | Year |
|---|---|
Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]).
Topics: Acute Pain; Adult; Aged; Aged, 80 and over; Analgesics; Area Under Curve; Chemoradiotherapy; Cranial | 2014 |
1 other study available for doxepin and Facial Pain
| Article | Year |
|---|---|
Role of depressive illness in the outcome of treatment of temporomandibular joint pain-dysfunction syndrome.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Chi-Square Distribution; Dental Occlusion; Depression | 1991 |